相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome
Fiorina Giona et al.
BLOOD (2012)
Polycythemia vera: gender-related phenotypic differences
Raffaele Landolfi et al.
INTERNAL AND EMERGENCY MEDICINE (2012)
JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms
Laura Villani et al.
LEUKEMIA RESEARCH (2012)
The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis
Jasper H. Smalberg et al.
BLOOD (2011)
The JAK2 46/1 haplotype in splanchnic vein thrombosis
Eirini Kouroupi et al.
BLOOD (2011)
JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy
Richard T. Silver et al.
LEUKEMIA RESEARCH (2011)
Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis
Donatella Colaizzo et al.
THROMBOSIS RESEARCH (2011)
A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms
Hans Carl Hasselbalch
EXPERT REVIEW OF HEMATOLOGY (2011)
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation
Valerio De Stefano et al.
ANNALS OF HEMATOLOGY (2010)
Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders
Brady L. Stein et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Treatment outcome in a cohort of young patients with polycythemia vera
Marco Ruggeri et al.
INTERNAL AND EMERGENCY MEDICINE (2010)
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
F. Passamonti et al.
LEUKEMIA (2010)
Clinical and hematological presentation of children and adolescents with polycythemia vera
Holger Cario et al.
ANNALS OF HEMATOLOGY (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients
Alberto Alvarez-Larran et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
Ola Landgren et al.
BLOOD (2008)
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
Francesco Passamonti et al.
BLOOD (2008)
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases
Jean-Jacques Kiladjian et al.
BLOOD (2008)
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
Dana E. Rollison et al.
BLOOD (2008)
Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?
Luciana Teofili et al.
HAEMATOLOGICA (2008)
Familial chronic myeloproliferative disorders: Clinical phenotype and evidence of disease anticipation
Elisa Rumi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
A. M. Vannucchi et al.
LEUKEMIA (2007)
Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
Naseema Gangat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia
Luciana Teofili et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Raffaele Landolfi et al.
BLOOD (2007)
The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis
D. Colaizzo et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis
Massimo Primignani et al.
HEPATOLOGY (2006)
Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression
Alison R. Moliterno et al.
BLOOD (2006)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
G Finazzi et al.
BLOOD (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
F Passamonti et al.
AMERICAN JOURNAL OF MEDICINE (2004)
分享论文
